21:39 , Jul 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Liver cancer In vitro, cell culture and mouse studies identified a SALL4-derived peptide inhibitor of the SALL4-RBBP4 interaction that could help treat hepatocellular carcinoma (HCC). Chemical synthesis and in vitro testing of analogs of a...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate of...
21:12 , Jun 29, 2018 |  BC Extra  |  Politics & Policy

Sen. Murray confronts BIO, PhRMA over harassment

Weeks after a backlash began against a biotech industry party that featured topless female dancers, Sen. Patty Murray (D-Wash.) sent letters Thursday to the heads of BIO and PhRMA asking what steps they are taking...
19:28 , Jun 15, 2018 |  BC Week In Review  |  Financial News

AAV plasmid company StrideBio raises $15.7M series A

StrideBio Inc. (Durham, N.C.) raised $15.7 million in a series A round led by existing investor Hatteras Venture Partners with participation from new investors Takeda Ventures, UCB Ventures and Alexandria Venture Investments. StrideBio COO Richard...
19:26 , Jun 13, 2018 |  BC Extra  |  Financial News

AAV plasmid company StrideBio raises $15.7M series A

StrideBio Inc. (Durham, N.C.) raised $15.7 million in a series A round led by existing investor Hatteras Venture Partners with participation from new investors Takeda Ventures, UCB Ventures and Alexandria Venture Investments. StrideBio COO Richard...
02:17 , Jun 9, 2018 |  BioCentury  |  Finance

ASCO ascent

Kinase inhibitor company Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) and cancer assay developer Genomic Health Inc. (NASDAQ:GHDX) each hit all-time highs in the wake of data readouts at the American Society of Clinical Oncology meeting in Chicago. Deciphera...
01:43 , Jun 9, 2018 |  BioCentury  |  Product Development

Past not prologue

Loxo Oncology Inc.’s two-year streak of stunning data at ASCO appears to be the result of good decisions on the back of a healthy dose of luck. But it will be a tall order to...
15:24 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

Deciphera reports updated Phase I data for DCC-2618 in GIST

Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) reported updated data at the American Society of Clinical Oncology (ASCO) meeting in Chicago from heavily pretreated patients with gastrointestinal stromal tumors (GIST) who received the company's DCC-2618 in a Phase...
23:40 , Jun 7, 2018 |  BC Innovations  |  Finance

Deerfield goes to school

Deerfield’s fourth umbrella agreement in the last eight months is a sign the firm is getting serious about creating newcos from academic discoveries. It thinks that with preset terms and unanimous buy-in, the model provides...
20:12 , Jun 4, 2018 |  BC Extra  |  Clinical News

Deciphera rises on GIST response data, proposes follow-on

Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) added $12.40 (48%) to $38.31 on Monday after reporting updated data from heavily pretreated patients with gastrointestinal stromal tumors who received the company's DCC-2618 in a Phase I trial. The data...